Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KOD
stocks logo

KOD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.058
+25.95%
--
--
-0.680
-37.61%
--
--
-0.700
-32.04%
Estimates Revision
The market is revising No Change the revenue expectations for Kodiak Sciences Inc. (KOD) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 157.41%.
EPS Estimates for FY2025
Revise Upward
up Image
+2.36%
In Past 3 Month
Stock Price
Go Up
up Image
+157.41%
In Past 3 Month
Wall Street analysts forecast KOD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KOD is 24.17 USD with a low forecast of 14.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast KOD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KOD is 24.17 USD with a low forecast of 14.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 23.810
sliders
Low
14.00
Averages
24.17
High
40.00
Current: 23.810
sliders
Low
14.00
Averages
24.17
High
40.00
H.C. Wainwright
Matthew Caufield
Buy
maintain
$24 -> $26
2025-11-17
Reason
H.C. Wainwright
Matthew Caufield
Price Target
$24 -> $26
2025-11-17
maintain
Buy
Reason
H.C. Wainwright analyst Matthew Caufield raised the firm's price target on Kodiak Sciences to $26 from $24 and keeps a Buy rating on the shares. The firm sees a near-term catalyst for shares from the Phase 3 GLOW2 trial in reformulated tarcocimab in diabetic retinopathy patients expected Q1.
H.C. Wainwright
Matthew Caufield
Neutral -> Buy
upgrade
$5 -> $24
2025-11-11
Reason
H.C. Wainwright
Matthew Caufield
Price Target
$5 -> $24
2025-11-11
upgrade
Neutral -> Buy
Reason
H.C. Wainwright analyst Matthew Caufield upgraded Kodiak Sciences to Buy from Neutral with a price target of $24, up from $5, after the company reported follow-up data from the Phase 1b APEX trial of KSI-101 in patients with macular edema secondary to inflammation. The data support continued best corrected visual acuity improvement and sustained retinal dryness, the analyst tells investors in a research note. H.C. Wainwright says its retinal work supports the prospects for KSI-101, and broader tarcocimab and KSI-501 retinal development.
JPMorgan
Neutral -> Overweight
upgrade
$15 -> $24
2025-10-24
Reason
JPMorgan
Price Target
$15 -> $24
2025-10-24
upgrade
Neutral -> Overweight
Reason
JPMorgan upgraded Kodiak Sciences to Overweight from Neutral with a price target of $24, up from $15. The firm believes the company's KSI-101 in macular edema secondary to inflammation is "de-risked" and could drive upside in the shares as the opportunity is better appreciated by the market. Data from the Phase 3 PEAK and PINNACLE studies of KSI-101 are anticipated in Q4 of 2026 and Q1 of 2027, respectively, the analyst tells investors in a research note.
LifeSci Capital
NULL
to
Outperform
initiated
$40
2025-10-23
Reason
LifeSci Capital
Price Target
$40
2025-10-23
initiated
NULL
to
Outperform
Reason
LifeSci Capital initiated coverage of Kodiak Sciences with an Outperform rating and $40 price target.
Barclays
Gena Wang
Underweight -> Equal Weight
upgrade
$7 -> $17
2025-09-25
Reason
Barclays
Gena Wang
Price Target
$7 -> $17
2025-09-25
upgrade
Underweight -> Equal Weight
Reason
Barclays analyst Gena Wang upgraded Kodiak Sciences to Equal Weight from Underweight with a price target of $17, up from $7. The firm says Roche's Phase 2 vamikibart plus ranibizumab data in diabetic macular edema provide "important clinical validation" Kodiak's for KSI-101. The clinical profiles are largely comparable and key opinion leader feedback suggest a low bar for practice adoption with KSI-101, the analyst tells investors in a research note.
Jefferies
initiated
$15
2025-09-22
Reason
Jefferies
Price Target
$15
2025-09-22
initiated
Reason
Jefferies initiated coverage of Kodiak Sciences (KOD) with a Buy rating and $15 price target. Kodiak has three drugs in Phase 3 study for eye diseases, each with key readouts in 2026, including lead asset '101 with data expected in Q4 of 2026 to Q1 of 2027, the analyst tells investors. A nearer-term catalyst may come from competitor Roche's (RHHBY) data expected soon at the AAO meeting, the analyst added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Kodiak Sciences Inc (KOD.O) is -7.61, compared to its 5-year average forward P/E of -6.12. For a more detailed relative valuation and DCF analysis to assess Kodiak Sciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.12
Current PE
-7.61
Overvalued PE
2.94
Undervalued PE
-15.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.65
Current EV/EBITDA
-4.47
Overvalued EV/EBITDA
4.79
Undervalued EV/EBITDA
-14.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.93
Current PS
0.00
Overvalued PS
5.50
Undervalued PS
-3.64
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

KOD News & Events

Events Timeline

(ET)
2025-11-13
16:12:50
Kodiak Sciences Announces Q3 EPS of $1.16, Exceeding Consensus Estimate of $1.04
select
2025-11-05 (ET)
2025-11-05
07:38:07
Kodiak Sciences Shares Findings from KSI-101 Study in MESI Patients
select
2025-09-15 (ET)
2025-09-15
07:02:17
Kodiak Sciences Reveals Latest Findings from APEX Study on KSI-101
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-14NASDAQ.COM
Kodiak Reports Larger-than-Expected Loss in Q3, Emphasizes Pipeline Development

  • Financial Performance: Kodiak Sciences reported a loss of $1.16 per share in Q3 2025, exceeding the expected loss of $1.07, with no approved products leading to zero revenue generation. Research and development expenses rose by 58% year-over-year to $50.5 million.

  • Clinical Trials: The company is conducting phase III studies for its candidates tarcocimab and KSI-501, targeting diabetic retinopathy and wet age-related macular degeneration, with top-line data expected in 2026.

  • Cash Position: As of September 30, 2025, Kodiak had $72 million in cash and marketable securities, a decrease from $104.2 million in June 2025, while its stock has surged 89.1% year-to-date.

  • Market Position: Kodiak holds a Zacks Rank #3 (Hold), while other biotech stocks like ANI Pharmaceuticals and Arcutis Biotherapeutics have better rankings and have shown significant earnings growth in recent months.

[object Object]
Preview
9.5
11-14PRnewswire
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

  • Recent Business Highlights: Kodiak Sciences reported strong clinical data and progress in its late-stage programs, particularly KSI-101 for macular edema, with significant vision improvements observed in patients and accelerated enrollment in Phase 3 studies.

  • Upcoming Catalysts: The company anticipates key data readouts in 2026 for its Phase 3 studies, including topline results for tarcocimab and KSI-501 in diabetic retinopathy and wet AMD, as well as continued advancements in its early-stage pipeline.

  • Financial Results: For Q3 2025, Kodiak Sciences reported a net loss of $61.5 million, an increase from the previous year, with R&D expenses rising due to heightened clinical activities and manufacturing efforts.

  • Company Overview: Kodiak Sciences focuses on developing innovative retinal therapies using its proprietary ABC platform, with three late-stage clinical programs targeting significant unmet needs in retinal diseases.

[object Object]
Preview
1.0
11-13PRnewswire
Kodiak Sciences to Present at Upcoming Investor Conferences

  • Upcoming Investor Conferences: Kodiak Sciences CEO Victor Perlroth will present at the Jefferies Global Healthcare Conference on November 17, 2025, and the 8th Annual Evercore Healthcare Conference on December 3, 2025, with live webcasts available on their website.

  • Company Focus: Kodiak Sciences is a precommercial biotechnology company dedicated to developing transformative therapeutics for retinal diseases, utilizing their proprietary ABC® Platform for next-generation retinal medicines.

  • Clinical Programs: The company is advancing three late-stage clinical programs, including Tarcocimab and KSI-501 in Phase 3 studies targeting retinal vascular diseases, and KSI-101 for Macular Edema Secondary to Inflammation.

  • Market Potential: Kodiak's therapies aim to address the $15 billion anti-VEGF market, focusing on preventing and treating leading causes of blindness globally.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Kodiak Sciences Inc (KOD) stock price today?

The current price of KOD is 23.81 USD — it has decreased -1.33 % in the last trading day.

arrow icon

What is Kodiak Sciences Inc (KOD)'s business?

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

arrow icon

What is the price predicton of KOD Stock?

Wall Street analysts forecast KOD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KOD is 24.17 USD with a low forecast of 14.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Kodiak Sciences Inc (KOD)'s revenue for the last quarter?

Kodiak Sciences Inc revenue for the last quarter amounts to -62.35M USD, increased 33.71 % YoY.

arrow icon

What is Kodiak Sciences Inc (KOD)'s earnings per share (EPS) for the last quarter?

Kodiak Sciences Inc. EPS for the last quarter amounts to -32940000.00 USD, increased 54.21 % YoY.

arrow icon

What changes have occurred in the market's expectations for Kodiak Sciences Inc (KOD)'s fundamentals?

The market is revising No Change the revenue expectations for Kodiak Sciences Inc. (KOD) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 157.41%.
arrow icon

How many employees does Kodiak Sciences Inc (KOD). have?

Kodiak Sciences Inc (KOD) has 109 emplpoyees as of December 13 2025.

arrow icon

What is Kodiak Sciences Inc (KOD) market cap?

Today KOD has the market capitalization of 1.26B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free